Video

ESMO 2022 VL

Radiographic Progression-Free Survival Correlation with Time-to-Event Endpoints in the VISION Trial - Michael Morris Details In this discussion, Michael Morris and Alicia Morgans discuss a post hoc analysis of the VISION Trial aimed at assessing earlier maturing time-to-event endpoints. Earlier time-to-event endpoints than overall survival (OS) will allow more timely regulatory approval and overall accelerated drug development. Morris and colleagues aimed to estimate correlations between time-to-event endpoints such as...
Results of Cohort K of the EV-103 Trial EV Monotherapy or in Combination With Pembro in Previously Untreated Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer - Guru... Details Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...
Predicting Efficacy of Both Nivolumab and of Nivolumab + Ipilimumab in Frontline mccRCC Patients, An Ancillary Analyses from the BIONIKK Randomized Trial - Maxime Meylan Details Pedro Barata is joined by Maxime Meylan to discuss a key ancillary analysis of the phase II BIONIKK trial aimed at understanding immune markers predictive of the efficacy of immune checkpoint inhibition as first-line therapy in metastatic clear cell renal cell carcinoma (mccRCC). This analysis demonstrates that the number of tertiary lymphoid structures and ki67+PD1+ density likely predict the eff...
Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-risk mHSPC, CYCLONE 3 - Rana McKay Details Rana McKay and Alicia Morgans discuss the CYCLONE 3 trial in progress in high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Recent data from the ARASENS trial shows a survival benefit for treatment intensification with ADT + docetaxel + a novel hormonal agent, triplet therapy, vs ADT + docetaxel in selected patients. Yet, there is a significant medical need to expand therapeutic optio...
MRI Versus Cystoscopic Staging for Newly Diagnosed Bladder Cancer, The BladderPath Trial - Nicholas James Details Nicholas James joins Alicia Morgans in a discussion of the first results of the novel BladderPath trial examining the role of magnetic resonance imaging (MRI) for bladder cancer staging. BladderPath is a randomized comparison of the time from the initial diagnosis to “correct” treatment among patients with possible muscle-invasive bladder cancer who receive staging with MRI, compared to TURBT. Nic...
rPFS Improvement Regardless of Mutations in Biomarker Subgroups in the Phase III PROpel Trial in First-Line Therapy for Patients with mCRPC - Fred Saad Details Fred Saad joins Alicia Morgans in a discussion focusing on the biomarker analysis and updated results from the Phase III PROpel trial of abiraterone and olaparib vs abiraterone and placebo as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). This updated analysis provides more detail on patients with HRR mutations in the PROpel trial. In this biomarker a...
8-month PSA Outcomes of Men with Metastatic Castration-Sensitive Prostate Cancer in the PEACE-1 Phase 3 Trial - Gwenaëlle Gravis Mescam Details Gwenaëlle Gravis joins Alicia Morgans in a discussion on the PEACE-1 phase 3 trial 8-month PSA outcomes of men with metastatic castration-sensitive prostate cancer (mCSPC). In the PEACE-1 study, investigators evaluated the efficacy and safety of abiraterone plus prednisone, with or without radiotherapy, in addition to standard of care in de novo mCSPC. The 8-month PSA decline to undetectable level...
Quality of Life and Patient-relevant Endpoints With Darolutamide in the ARASENS Trial - Karim Fizazi Details Alicia Morgans and Karim Fizazi discuss quality of life and patient-relevant endpoints with darolutamide in the phase 3 ARASENS study and which patient populations benefit most from this data. Dr Fizazi also details the P6 platform. P6 is for all patients with metastatic castration-sensitive disease. There are different phase three trials called P6. Drs Morgans and Fizazi discuss the P6 vulnerable...
Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard Details Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...
The ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer: Benefits In the Urologic Clinical Practice - Neal Shore Details Alicia Morgans is joined by Neal Shore, who provides his perspective on the phase 3 ARASENS data for patients with metastatic hormone-sensitive prostate cancer, which demonstrates the superiority in terms of survival and numerous other secondary endpoints of triplet versus doublet therapy. In ARASENS, darolutamide + androgen-deprivation therapy (ADT) + docetaxel significantly reduced risk of death...

ESMO 2022 VL

Login